DZ3155A1 - Nouvelle composition pharmaceutique. - Google Patents

Nouvelle composition pharmaceutique.

Info

Publication number: DZ3155A1
Authority: DZ; Algeria
Prior art keywords: pharmaceutical composition; new pharmaceutical; new; composition; pharmaceutical
Prior art date: 1999-04-23

Application number

DZ003155A

Other languages

English (en)

French (fr)

Inventor

Paul David James Blackler

Robert Gordon Cilles

Michael John Sasse

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-23

Filing date

2000-04-19

Publication date

2000-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ3155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-04-23 Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en

1999-05-25 Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en

2000-04-19 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2000-11-02 Application granted granted Critical

2000-11-02 Publication of DZ3155A1 publication Critical patent/DZ3155A1/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Steroid Compounds (AREA)

DZ003155A 1999-04-23 2000-04-19 Nouvelle composition pharmaceutique. DZ3155A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9909472.4A GB9909472D0 (en)	1999-04-23	1999-04-23	Novel compounds
GBGB9912197.2A GB9912197D0 (en)	1999-05-25	1999-05-25	Novel pharmaceutical
PCT/GB2000/001514 WO2000064892A2 (en)	1999-04-23	2000-04-19	Thiazolidinedione derivative and its use as antidiabetic

Publications (1)

Publication Number	Publication Date
DZ3155A1 true DZ3155A1 (fr)	2000-11-02

Family

ID=26315460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ003155A DZ3155A1 (fr)	1999-04-23	2000-04-19	Nouvelle composition pharmaceutique.

Country Status (40)

Country	Link
US (2)	US6815457B1 (de)
EP (3)	EP1284268B1 (de)
JP (1)	JP2002543075A (de)
KR (1)	KR100744359B1 (de)
CN (1)	CN1208335C (de)
AP (1)	AP1495A (de)
AR (2)	AR023568A1 (de)
AT (2)	ATE382046T1 (de)
AU (1)	AU765498B2 (de)
BG (1)	BG65427B1 (de)
BR (1)	BR0009934A (de)
CA (1)	CA2370258A1 (de)
CO (1)	CO5170424A1 (de)
CY (1)	CY1107238T1 (de)
CZ (1)	CZ20013799A3 (de)
DE (2)	DE60037602T2 (de)
DK (2)	DK1173434T3 (de)
DZ (1)	DZ3155A1 (de)
EA (1)	EA004534B1 (de)
ES (2)	ES2204557T3 (de)
HK (1)	HK1045154B (de)
HR (1)	HRP20010773B1 (de)
HU (1)	HUP0200929A3 (de)
IL (1)	IL146110A0 (de)
MA (1)	MA26785A1 (de)
MX (1)	MXPA01010820A (de)
MY (1)	MY128007A (de)
NO (1)	NO320589B1 (de)
NZ (1)	NZ515163A (de)
OA (1)	OA11871A (de)
PE (1)	PE20010040A1 (de)
PL (1)	PL351686A1 (de)
PT (2)	PT1173434E (de)
RS (1)	RS50114B (de)
SK (1)	SK286423B6 (de)
TR (1)	TR200103061T2 (de)
TW (1)	TW591027B (de)
UA (1)	UA67843C2 (de)
UY (1)	UY26120A1 (de)
WO (1)	WO2000064892A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6664278B2 (en)	1997-12-16	2003-12-16	Smithkline Beecham P.L.C.	Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en)	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
US20020137940A1 (en) *	1997-12-16	2002-09-26	Smithkline Beecham P.L.C.	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
AR023561A1 (es)	1999-04-23	2002-09-04	Smithkline Beecham Corp	Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
US20040248945A1 (en)	1999-04-23	2004-12-09	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
HRP20010773B1 (en)	1999-04-23	2005-06-30	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
GB0006133D0 (en)	2000-03-14	2000-05-03	Smithkline Beecham Plc	Novel pharmaceutical
US7241895B2 (en) *	2000-09-26	2007-07-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
CA2426117A1 (en) *	2000-09-26	2002-04-04	Dr. Reddy's Laboratories Limited	Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
AU2002352391A1 (en) *	2001-12-13	2003-06-23	Smithkline Beecham Plc	A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0130511D0 (en) *	2001-12-20	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
WO2003053962A1 (en) *	2001-12-20	2003-07-03	Smithkline Beecham Plc	5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0307259D0 (en) *	2003-03-28	2003-05-07	Glaxo Group Ltd	Process
EP1468997A3 (de) *	2003-04-18	2004-11-03	CHEMI S.p.A.	Polymorphe Formen von Rosiglitazon Maleat
GB2405403A (en) *	2003-08-29	2005-03-02	Cipla Ltd	Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (de) *	2004-01-28	2006-10-11	Usv Limited	Verfahren zur herstellung von 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]phenylmethyl]thiazolidin-2,4-dionmaleat
ITMI20041537A1 (it) *	2004-07-28	2004-10-28	Chemi Spa	Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) *	2005-05-24	2007-09-26	Zentiva, A. S.	Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) *	2006-05-09	2008-10-14	Teva Pharmaceutical Industries, Ltd.	2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched rosiglitazone
EP2184055A1 (de)	2008-11-07	2010-05-12	LEK Pharmaceuticals d.d.	Verfahren zur Herstellung fester Dosierungsformen von Rosiglitazonmaleat

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE186724T1 (de)	1987-09-04	1999-12-15	Beecham Group Plc	Substituierte thiazolidindionderivate
US6288095B1 (en)	1987-09-04	2001-09-11	Beecham Group P.L.C.	Compounds
GB9124513D0 (en)	1991-11-19	1992-01-08	Smithkline Beecham Plc	Novel process
GB9218830D0 (en)	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
US5741803A (en)	1992-09-05	1998-04-21	Smithkline Beecham Plc	Substituted thiazolidinedionle derivatives
US5457109A (en) *	1993-09-15	1995-10-10	Warner-Lambert Company	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4404198A1 (de)	1994-02-10	1995-08-17	Henkel Kgaa	2-Fluor-6-nitroaniline
US20010044458A1 (en) *	1994-02-10	2001-11-22	Smithkline Beechamp P.L.C.	Use of insulin sensitisers for treating renal diseases
WO1995021608A1 (en)	1994-02-10	1995-08-17	Smithkline Beecham Plc	Use of insulin sensitisers for treating renal diseases
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) *	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
GB9711683D0 (en)	1997-06-05	1997-08-06	Smithkline Beecham Plc	Composition
US20010049380A1 (en) *	1997-06-18	2001-12-06	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and sulphonylurea
WO1998057635A1 (en)	1997-06-18	1998-12-23	Smithkline Beecham Plc	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
EP1671637A3 (de)	1997-06-18	2007-12-19	SmithKline Beecham P.L.C.	Behandlung der Diabetes mit Thiazolidindione und Sulphonylurea
US20020004515A1 (en) *	1997-06-18	2002-01-10	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and metformin
US20020028768A1 (en) *	1997-06-18	2002-03-07	Smithkline Beecham P.L.C.	Treatment of diabetes with rosiglitazone and insulin
TR199903057T2 (xx)	1997-06-18	2000-04-21	Smithkline Beecham Plc	Diabetin tiazolidinedion ve metformin ile tedavisi.
GB9712866D0 (en)	1997-06-18	1997-08-20	Smithkline Beecham Plc	Novel method of treatment
US20020045649A1 (en) *	1997-07-18	2002-04-18	Smithkline Beecham P.L.C.	Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020016287A1 (en) *	1997-07-18	2002-02-07	Smithkline Beecham P.L.C.	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9726568D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
GB9726563D0 (en)	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
US20020137940A1 (en)	1997-12-16	2002-09-26	Smithkline Beecham P.L.C.	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en)	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
CZ20013801A3 (cs)	1999-04-23	2002-07-17	Smithkline Beecham Plc	Nový léčivý přípravek
AR023561A1 (es)	1999-04-23	2002-09-04	Smithkline Beecham Corp	Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
HRP20010773B1 (en)	1999-04-23	2005-06-30	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
CA2426117A1 (en)	2000-09-26	2002-04-04	Dr. Reddy's Laboratories Limited	Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

2000
- 2000-04-19 HR HR20010773A patent/HRP20010773B1/xx not_active IP Right Cessation
- 2000-04-19 CN CNB008090572A patent/CN1208335C/zh not_active Expired - Fee Related
- 2000-04-19 HK HK02104882.1A patent/HK1045154B/en not_active IP Right Cessation
- 2000-04-19 OA OA1200100275A patent/OA11871A/en unknown
- 2000-04-19 US US10/030,323 patent/US6815457B1/en not_active Expired - Fee Related
- 2000-04-19 DZ DZ003155A patent/DZ3155A1/xx active
- 2000-04-19 WO PCT/GB2000/001514 patent/WO2000064892A2/en not_active Ceased
- 2000-04-19 EA EA200101119A patent/EA004534B1/ru not_active IP Right Cessation
- 2000-04-19 IL IL14611000A patent/IL146110A0/xx unknown
- 2000-04-19 EP EP02080320A patent/EP1284268B1/de not_active Expired - Lifetime
- 2000-04-19 MX MXPA01010820A patent/MXPA01010820A/es unknown
- 2000-04-19 AR ARP000101870A patent/AR023568A1/es unknown
- 2000-04-19 KR KR1020017013557A patent/KR100744359B1/ko not_active Expired - Fee Related
- 2000-04-19 DK DK00920889T patent/DK1173434T3/da active
- 2000-04-19 JP JP2000614244A patent/JP2002543075A/ja active Pending
- 2000-04-19 AU AU41306/00A patent/AU765498B2/en not_active Ceased
- 2000-04-19 DE DE60037602T patent/DE60037602T2/de not_active Expired - Fee Related
- 2000-04-19 DK DK02080320T patent/DK1284268T3/da active
- 2000-04-19 PL PL00351686A patent/PL351686A1/xx not_active Application Discontinuation
- 2000-04-19 NZ NZ515163A patent/NZ515163A/xx unknown
- 2000-04-19 AT AT02080320T patent/ATE382046T1/de not_active IP Right Cessation
- 2000-04-19 AT AT00920889T patent/ATE247653T1/de not_active IP Right Cessation
- 2000-04-19 EP EP00920889A patent/EP1173434B1/de not_active Expired - Lifetime
- 2000-04-19 CZ CZ20013799A patent/CZ20013799A3/cs unknown
- 2000-04-19 PT PT00920889T patent/PT1173434E/pt unknown
- 2000-04-19 PE PE2000000364A patent/PE20010040A1/es not_active Application Discontinuation
- 2000-04-19 SK SK1491-2001A patent/SK286423B6/sk not_active IP Right Cessation
- 2000-04-19 HU HU0200929A patent/HUP0200929A3/hu not_active IP Right Cessation
- 2000-04-19 UA UA2001117938A patent/UA67843C2/uk unknown
- 2000-04-19 TR TR2001/03061T patent/TR200103061T2/xx unknown
- 2000-04-19 PT PT02080320T patent/PT1284268E/pt unknown
- 2000-04-19 BR BR0009934-1A patent/BR0009934A/pt not_active Application Discontinuation
- 2000-04-19 AP APAP/P/2001/002333A patent/AP1495A/en active
- 2000-04-19 AR ARP000101865A patent/AR023564A1/es unknown
- 2000-04-19 DE DE60004658T patent/DE60004658T2/de not_active Expired - Fee Related
- 2000-04-19 CO CO00028932A patent/CO5170424A1/es not_active Application Discontinuation
- 2000-04-19 ES ES00920889T patent/ES2204557T3/es not_active Expired - Lifetime
- 2000-04-19 RS YUP-752/01A patent/RS50114B/sr unknown
- 2000-04-19 EP EP07150378A patent/EP1903043A1/de not_active Withdrawn
- 2000-04-19 CA CA002370258A patent/CA2370258A1/en not_active Abandoned
- 2000-04-19 ES ES02080320T patent/ES2298327T3/es not_active Expired - Lifetime
- 2000-04-21 MY MYPI20001707A patent/MY128007A/en unknown
- 2000-04-24 TW TW089107633A patent/TW591027B/zh not_active IP Right Cessation
- 2000-04-24 UY UY26120A patent/UY26120A1/es not_active Application Discontinuation
2001
- 2001-10-22 NO NO20015149A patent/NO320589B1/no unknown
- 2001-10-22 MA MA26377A patent/MA26785A1/fr unknown
- 2001-11-20 BG BG106119A patent/BG65427B1/bg unknown
2003
- 2003-11-07 US US10/703,887 patent/US20040092555A1/en not_active Abandoned
2008
- 2008-03-12 CY CY20081100277T patent/CY1107238T1/el unknown

Also Published As

Publication number	Publication date
EP1173434A2 (de)	2002-01-23
SK286423B6 (sk)	2008-09-05
CN1355801A (zh)	2002-06-26
CA2370258A1 (en)	2000-11-02
EP1284268B1 (de)	2007-12-26
DK1284268T3 (da)	2008-04-28
HUP0200929A2 (en)	2002-08-28
EA004534B1 (ru)	2004-06-24
HK1055293A1 (en)	2004-01-02
AR023568A1 (es)	2002-09-04
MA26785A1 (fr)	2004-12-20
KR100744359B1 (ko)	2007-07-30
EP1903043A1 (de)	2008-03-26
DE60037602D1 (de)	2008-02-07
PL351686A1 (en)	2003-06-02
HK1045154A1 (en)	2002-11-15
CZ20013799A3 (cs)	2002-04-17
EP1284268A1 (de)	2003-02-19
UA67843C2 (uk)	2004-07-15
HUP0200929A3 (en)	2004-03-29
MY128007A (en)	2007-01-31
MXPA01010820A (es)	2002-06-04
DK1173434T3 (da)	2003-12-08
RS50114B (sr)	2009-03-25
CY1107238T1 (el)	2012-11-21
HRP20010773B1 (en)	2005-06-30
PT1173434E (pt)	2003-12-31
NO320589B1 (no)	2005-12-27
US6815457B1 (en)	2004-11-09
EA200101119A1 (ru)	2002-04-25
TW591027B (en)	2004-06-11
AU765498B2 (en)	2003-09-18
ES2204557T3 (es)	2004-05-01
ES2298327T3 (es)	2008-05-16
KR20020028873A (ko)	2002-04-17
ATE382046T1 (de)	2008-01-15
AP1495A (en)	2005-11-30
UY26120A1 (es)	2000-12-29
BR0009934A (pt)	2002-06-04
EP1173434B1 (de)	2003-08-20
YU75201A (sh)	2004-09-03
PE20010040A1 (es)	2001-03-10
WO2000064892A3 (en)	2001-01-25
OA11871A (en)	2006-03-27
BG106119A (en)	2002-05-31
ATE247653T1 (de)	2003-09-15
JP2002543075A (ja)	2002-12-17
AU4130600A (en)	2000-11-10
NO20015149L (no)	2001-12-17
HRP20010773A2 (en)	2002-10-31
DE60037602T2 (de)	2009-01-08
WO2000064892A2 (en)	2000-11-02
DE60004658D1 (de)	2003-09-25
NZ515163A (en)	2004-02-27
TR200103061T2 (tr)	2002-05-21
US20040092555A1 (en)	2004-05-13
CO5170424A1 (es)	2002-06-27
HK1045154B (en)	2004-06-25
BG65427B1 (bg)	2008-07-31
CN1208335C (zh)	2005-06-29
PT1284268E (pt)	2008-03-10
AR023564A1 (es)	2002-09-04
IL146110A0 (en)	2002-07-25
SK14912001A3 (sk)	2002-02-05
DE60004658T2 (de)	2004-06-24
NO20015149D0 (no)	2001-10-22

Publication	Publication Date	Title
MA26937A1 (fr)	2004-12-20	Nouvelle composition pharmaceutique.
FI991485L (fi)	2000-12-31	Uusi farmaseuttinen koostumus
NO20015175L (no)	2001-10-23	Farmasöytisk sammensetning
FR2775596B1 (fr)	2004-12-24	Nouvelles compositions pharmaceutiques
ID27415A (id)	2001-04-05	Komposisi farmaseutik
PT1242087E (pt)	2004-06-30	Composicoes farmaceuticas
TR199901077A3 (tr)	1999-12-21	Ispençiyari formülasyonlar.
FR2705566B1 (fr)	1996-04-05	Nouvelles compositions pharmaceutiques.
DZ2516A1 (fr)	2004-11-08	Composition pharmaceutique en aérosol.
MA26497A1 (fr)	2004-12-20	Nouvelle formulation pharmaceutique
ID29262A (id)	2001-08-16	Komposisi farmasi
TR199802624A3 (tr)	1999-10-21	Yeni farmasötik.
ID27201A (id)	2001-03-08	Komposisi farmasi
EP1408896A4 (de)	2010-02-24	Pharmazeutische zusammensetzung
NO20014926L (no)	2001-12-13	Farmasöytiske forbindelser
DZ3164A1 (fr)	2000-11-02	Nouvel agent pharmaceutique.
PT1239832E (pt)	2004-10-29	Composicoes farmaceuticas
DE60037421D1 (de)	2008-01-24	Stopfbuchspackung
ID29294A (id)	2001-08-16	Komposisi farmasi
PT1227817E (pt)	2004-11-30	Composicao farmaceutica aquosa contendo ciclesonida
MA26531A1 (fr)	2004-12-20	Composition pharmaceutique
FI4488U1 (fi)	2000-07-20	Farmaseuttinen koostumus
DZ3163A1 (fr)	2000-10-26	Nouvelle substance pharmaceutique.
ID25857A (id)	2000-11-09	Komposisi farmasi
FR2779145B1 (fr)	2004-07-30	Nouvelles compositions pharmaceutiques